Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice-Reference-Cited by-同舟云学术

Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

Published:2017-10-04 Issue:55 Volume:8 Page:94040-94053
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Reeves Patrick M.¹,Abbaslou Mojgan A.¹,Kools Farah R.W.¹,Vutipongsatorn Kritchai¹,Tong Xiaoyun¹,Gavegnano Christina²,Schinazi Raymond F.²,Poznansky Mark C.¹

Affiliation:

1. Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA

2. Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells;Translational Oncology;2024-06

2. Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway;International Journal of Biological Sciences;2024

3. Ascites in malignant ovarian cancer confer ovarian cancer cells chemoresistance to platinum. Combination treatment with crizotinib and 2-hydroxyestradiol restores platinum sensitivity;2023-09-24

4. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer;Journal of Obstetrics and Gynaecology Research;2023-08-10

5. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor;Science Translational Medicine;2023-06-21